Ticlopidine and Platelet Function

• References

• 1 Berglund U, von Schenck H, Wallentin L. Effects of ticlopidine on platelet function in men with stable angina pectoris. Thromb Haemostas 1985; 54: 808-812
• 2 Lecrubier C, Conard J, Samama M, Bousser MG. Essai randomise d’un nouvel agent anti-agrégant: la ticlopidine. Therapie 1977; 32: 189-194
• 3 Conard J, Lecrubier C, Scarabin PY, Horellou MH, Samama M, Bousser MG. Effects of long-term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 1980; 20: 143-148
• 4 Lecompte T, Lecrubier C, Bouloux C, Galleyrand J, Maffrand JP, Samama M. Addition de 40 mg/jour d’aspirine pendant une semaine à un traitement par ticlopidine ou placebo. Groupe d’Etudes sur l’Hémostase et la Thrombose Societé Française d’Hématologie Paris: October 25th 1985
• 5 Sinzinger H, Kaliman J, Widhalm K, Pachinger O, Probst P. Value of platelet sensitivity to antiaggregatory prostaglandins (PGI2, PGE1, PGD2) in 50 patients with myocardial infarction at young age. Protaglandins Med 1981; 7: 125-132
• 6 Lagarde M, Berciaud P, Burtin M, Dechavanne M. Refractoriness of diabetic platelets to inhibitory protaglandins. Prostaglandins Med 1981; 7: 341-347
• 7 Sheperd GL, Lewis PJ, Blair IA, de Mey C, MacDermot J. Epoprostenol binding and activation of adenylate cyclase in platelets of diabetic and control subjects. Br J Clin Pharmac 1983; 15: 77-81
• 8 Stoltz JF, Solagna S, Nicolas A, Verry M. Study of a membrane physicochemical mechanism of the platelet antiaggregating effect of ticlopidine. Thromb Haemostas 1981; 46: 412 (Abstr)
• 9 Daveloose D, Sablayrolles M, Molle D, Letterrier F. Interaction of ticlopidine with the erythrocyte membrane. Biochem Pharmacol 1982; 31: 3949-3954
• 10 Siess W, Dray F. Very low levels of 6-keto-prostaglandin F1α in human plasma. J Lab Clin Med 1981; 99: 388-398
• 11 Blair IA, Barrow SE, Waddell KA, Lewis PJ, Dollery CT. Prostacyclin is not a circulating hormone in man. Prostaglandins 1982; 23: 579-589
• 12 Fitzgerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 1981; 68: 1272-1276
• 13 Fitzgerald GA, Smith B, Pedersen AK, Brash AR. Endogenous prostacyclin biosynthesis is enhanced in the presence of atherosclerosis and platelet activation in man. Thromb Haemostas 1983; 50: 71 (Abstr)
• 14 Neri SerneriG G, Masotti G, Poggesi L, Galanti G, Morettini A, Scarti L. Reduced prostacyclin production in patients with different manifestations of ischemic heart disease. Am J Cardiol 1982; 49: 1146-1150
• 15 Pickles H, O’Grady J. Side-effects occurring during administration of epoprostenol in man. Br J Clin Pharmac 1982; 14: 177-185
• 16 Lecrubier C, Girard P, Noire P, Samama M. Comparative study of platelet aggregation measured by 3 different methods (photometric and impedance) in ticlopidine treated patients Agents Actions suppl 1984; 15: 60-67
• 17 Randon J, Lefort J, Vargaftig B. Comparison between the anti-aggregating effect of ticlopidine in whole blood, PRP and washed platelets in the rat. Thromb Res 1982; 26: 13-20
• 18 Haslam RJ, McClenaghan MD. Measurement of circulating prostacyclin. Nature 1981; 292: 364-366